Laudexium metilsulfate

Laudexium metilsulfate
Clinical data
Other names	Laudolissin
Routes of; administration	IV
Legal status
Legal status	discontinued from clinical use;
Pharmacokinetic data
Bioavailability	100% (IV)
Identifiers
	IUPAC name 1-[(3,4-Dimethoxyphenyl)methyl]-2-[10-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]decyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium methyl sulfate;
CAS Number	3253-60-9 ;
PubChem CID	18618;
ChemSpider	17584 ;
UNII	D067KDG4NU;
CompTox Dashboard (EPA)	DTXSID301029355 ;
Chemical and physical data
Formula	C54H80N2O16S2
Molar mass	1077.35 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCCCCCCCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-];
	InChI InChI=1S/C52H74N2O8.2CH4O4S/c1-53(27-23-39-33-49(59-7)51(61-9)35-41(39)43(53)29-37-19-21-45(55-3)47(31-37)57-5)25-17-15-13-11-12-14-16-18-26-54(2)28-24-40-34-50(60-8)52(62-10)36-42(40)44(54)30-38-20-22-46(56-4)48(32-38)58-6;21-5-6(2,3)4/h19-22,31-36,43-44H,11-18,23-30H2,1-10H3;21H3,(H,2,3,4)/q+2;;/p-2 ; Key:LADQAYSLFLCKOD-UHFFFAOYSA-L ;
	(what is this?) (verify)

Laudexium metilsulfate is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in surgical anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Laudexium^[1] is no longer used in clinical practice, though it was introduced clinically in the early 1950s.^{[citation needed]} It has about half the potency, a slower onset of action and a duration of action much longer than that of d-tubocurarine.^[2] As with all clinically established (as well as experimental agents) with a non-depolarizing mechanism of action, its pharmacological action can be antagonized by anticholinesterases.

The displacement of laudexium from clinical use was assured owing to recurrent reports of significant post-operative re-curarization.^[3]

References

^ Taylor EP (1952). "Synthetic neuromuscular blocking agents. Part II. Bis(quaternary ammonium salts) derived from laudanosine". J Chem Soc: 142–145. doi:10.1039/JR9520000142.
^ Hunter AR (February 1955). "The action of laudexium in man and experimental animals" (PDF). British Journal of Anaesthesia. 27 (2): 73–9. doi:10.1093/bja/27.2.73. PMID 13230365.
^ Collier HO, Macauley B (September 1952). "The pharmacological properties of "laudolissin" a long-acting curarizing agent". British Journal of Pharmacology and Chemotherapy. 7 (3): 398–408. doi:10.1111/j.1476-5381.1952.tb00707.x. PMC 1509112. PMID 12978243.

External links

Neuromuscular+blocking+agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

[1] Taylor EP (1952). "Synthetic neuromuscular blocking agents. Part II. Bis(quaternary ammonium salts) derived from laudanosine". J Chem Soc: 142–145. doi:10.1039/JR9520000142.

[2] Hunter AR (February 1955). "The action of laudexium in man and experimental animals" (PDF). British Journal of Anaesthesia. 27 (2): 73–9. doi:10.1093/bja/27.2.73. PMID 13230365.

[3] Collier HO, Macauley B (September 1952). "The pharmacological properties of "laudolissin" a long-acting curarizing agent". British Journal of Pharmacology and Chemotherapy. 7 (3): 398–408. doi:10.1111/j.1476-5381.1952.tb00707.x. PMC 1509112. PMID 12978243.

[1]

[2]

[3]